Daily non-political popular news in brief.
Interferon does not slow or stop hepatitis C from worsening, study finds
11-08-2007 · EurekAlert!Interferon does not slow or halt the progression of chronic hepatitis C and advanced liver disease in patients who haven't responded to previous attempts to eradicate the disease, a national study has found. Patients who were treated with interferon did experience a significant decrease in viral levels and liver inflammation, but the trial unequivocally demonstrated that treatment with interferon does not prevent the worsening of liver disease in patients who've failed prior treatments.
Read more »
Keywords: interferon, slow, stop, hepatitis, worsening, study, hepatiti
« Previous | Next »
Similar news on "Interferon does not slow or stop hepatitis C from worsening, study finds":
- Hepatitis C treatment reduces the virus but serious liver problems may progress
11-06-2007 · EurekAlert!
Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon. However, the treatment did not slow or prevent the progression of serious liver disease. These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis, and were reported at the annual meeting of the American Association for the Study of Liver Disease
Similar news · Read more »
- Study links faulty DNA repair to Huntington's disease onset
04-22-2007 · EurekAlert!
Huntington's disease, an inherited neurodegenerative disorder that affects roughly 30,000 Americans, is incurable and fatal. But a new discovery about how cells repair their DNA points to a possible way to stop or slow the onset of the disease. The research was funded by the National Institutes of Health.
Similar news · Read more »
- 24-week course of interferon-alpha therapy prolongs survival in patients hepatitis C virus
11-02-2007 · EurekAlert!
A group at Hiroshima University Hospital performed a matched historical controlled study on whether a 24-week course of interferon-alpha therapy, after curative treatment for primary hepatocellular carcinoma associated with hepatitis C virus, could influence tumor recurrence, patient survival, and liver function. Patients with sustained virological responses had reduced recurrence, prolonged survival and a preserved liver function. The group also determined that viral eradication was the most important factor in such patients.
Similar news · Read more »
- Interferon-treated hepatitis C patients likely to experience retinopathy
01-03-2007 · EurekAlert!
Persons with chronic hepatitis C being treated with Interferon (IFN) are at risk of developing retinopathy as early as two weeks into treatment according to the results of a new study published in the January 2007 issue of Investigative Ophthalmology & Visual Science (IOVS).
Similar news · Read more »
- Stanford researchers identify immune dysfunction in melanoma patients
05-07-2007 · EurekAlert!
Researchers at Stanford have begun to shed light on why the human immune system isn't able to stop such cancers as melanoma, suggesting answers that could pave the way for better treatment of this often-fatal illness. In a small study, the scientists found that the immune cells in a majority of people with this deadly skin cancer fail to respond properly to a molecule called interferon, which normally activates the immune system.
Similar news · Read more »
- PrEP strategy could dramatically slow the spread of HIV
09-18-2007 · EurekAlert!
A University of Pittsburgh study published in PLoS ONE reports that giving a daily antiretroviral pill to people could profoundly slow the spread of the infection in sub-Saharan Africa by potentially preventing 3.2 million cases in 10 years. The findings are based on a mathematical model developed to predict the public-health impact of pre-exposure chemoprophylaxis -- an HIV prevention strategy that uses antiretroviral drugs to stop the infection from occurring in the first place.
Similar news · Read more »
- Numerous factors affect success of interferon treatment for hepatitis C
07-02-2007 · EurekAlert!
A new study on predicting outcomes of standard treatment for hepatitis C virus (HCV) infection found that a number of factors impacted responses, including the form of the interferon given. However, for some genotypes of the disease, few of these factors play a role.
Similar news · Read more »
- In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment
12-27-2007 · EurekAlert!
As reported recently in the journal Hepatology, WIN-R, a multicenter study of over 5,000 patients with hepatitis C virus showed treatment with weight-based REBETOL® (ribavirin, USP) in combination with pegylated interferon alfa-2b achieved significantly higher rates of sustained virologic response and lower relapse rates compared to combination therapy using a flat dose of RBV 800 mg/day.
Similar news · Read more »
- People with early Parkinson's report hallucinations, sleepiness
07-09-2007 · EurekAlert!
People with early Parkinson's disease report a higher than anticipated development or worsening of hallucinations, sleepiness, and swelling. Researchers have identified factors that make people more likely to develop these problems, according to a study published in the July 10, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.
Similar news · Read more »
- Hepatitis C increases risk of non-Hodgkin lymphoma
05-08-2007 · EurekAlert!
Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma (malignancy involving lymphatic tissue) of 20 percent to 30 percent, and a three-fold increase in the risk of another type of lymphoma, according to a study in the May 9 issue of JAMA.
Similar news · Read more »
